We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novavax's (NVAX) COVID-19 Vaccine Shows Final Efficacy of 96.4%
Read MoreHide Full Article
Novavax, Inc.’s (NVAX - Free Report) final data from a pivotal phase III study evaluating its coronavirus vaccine candidate, NVX-CoV2373, showed that it was 96.4% effective against mild, moderate and severe disease caused by the original COVID-19 strain in the United Kingdom.
The company also announced results from the complete analysis of its phase IIb study in South Africa. In the region marked by a vast majority of strains that are B1.351 escape variants, the vaccine candidate delivered 55.4% efficiency among the HIV-negative study participants.
Importantly, both studies conducted by the company have met statistical success parameters. Also, NVX-CoV2373 demonstrated 100% protection against severe disease and significantly reduced mild and moderate diseases across both the studies.
Novavax is planning to submit the data for authorization to several regulatory agencies worldwide.
Shares of Novavax were up 8.1% on Friday following the announcement of the news on Thursday. In fact, the stock has rallied 81.8% so far this year compared with the industry’s increase of 1.7%.
Notably, NVX-CoV2373 demonstrated 86.3% efficacy against the new circulating variant, B.1.1.7/501Y.V1, in the United Kingdom. The primary efficacy endpoint showed an overall vaccine efficacy of 89.7%.
We remind investors that in January 2021, Novavax announced that the phase III study evaluating NVX-CoV2373 in the United Kingdom met the primary endpoint, demonstrating a vaccine efficacy of 89.3%.
Please note that Novavax is conducting the phase III PREVENT-19 study, which is evaluating the efficacy, safety and immunogenicity of NVX-CoV2373 in the United States and Mexico.
We note that several companies have already launched vaccines for fighting the COVID-19 virus.
Earlier this month, Johnson & Johnson’s (JNJ - Free Report) single-dose COVID-19 vaccine candidate was granted Conditional Marketing Authorization by the European Commission, making it the fourth COVID-19 vaccine to be available in Europe.
J&J’s vaccine was granted Emergency Use Authorization by the FDA last month.
Notably, other available vaccines include Pfizer (PFE - Free Report) /BioNTech’s BNT162b2, Moderna’s (MRNA - Free Report) mRNA-1273 and AstraZeneca’s COVID-19 vaccine.
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Image: Shutterstock
Novavax's (NVAX) COVID-19 Vaccine Shows Final Efficacy of 96.4%
Novavax, Inc.’s (NVAX - Free Report) final data from a pivotal phase III study evaluating its coronavirus vaccine candidate, NVX-CoV2373, showed that it was 96.4% effective against mild, moderate and severe disease caused by the original COVID-19 strain in the United Kingdom.
The company also announced results from the complete analysis of its phase IIb study in South Africa. In the region marked by a vast majority of strains that are B1.351 escape variants, the vaccine candidate delivered 55.4% efficiency among the HIV-negative study participants.
Importantly, both studies conducted by the company have met statistical success parameters. Also, NVX-CoV2373 demonstrated 100% protection against severe disease and significantly reduced mild and moderate diseases across both the studies.
Novavax is planning to submit the data for authorization to several regulatory agencies worldwide.
Shares of Novavax were up 8.1% on Friday following the announcement of the news on Thursday. In fact, the stock has rallied 81.8% so far this year compared with the industry’s increase of 1.7%.
Notably, NVX-CoV2373 demonstrated 86.3% efficacy against the new circulating variant, B.1.1.7/501Y.V1, in the United Kingdom. The primary efficacy endpoint showed an overall vaccine efficacy of 89.7%.
We remind investors that in January 2021, Novavax announced that the phase III study evaluating NVX-CoV2373 in the United Kingdom met the primary endpoint, demonstrating a vaccine efficacy of 89.3%.
Please note that Novavax is conducting the phase III PREVENT-19 study, which is evaluating the efficacy, safety and immunogenicity of NVX-CoV2373 in the United States and Mexico.
We note that several companies have already launched vaccines for fighting the COVID-19 virus.
Earlier this month, Johnson & Johnson’s (JNJ - Free Report) single-dose COVID-19 vaccine candidate was granted Conditional Marketing Authorization by the European Commission, making it the fourth COVID-19 vaccine to be available in Europe.
J&J’s vaccine was granted Emergency Use Authorization by the FDA last month.
Notably, other available vaccines include Pfizer (PFE - Free Report) /BioNTech’s BNT162b2, Moderna’s (MRNA - Free Report) mRNA-1273 and AstraZeneca’s COVID-19 vaccine.
Zacks Rank
Novavax currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 77 billion devices by 2025, creating a $1.3 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 4 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2022.
Click here for the 4 trades >>